{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:45:49Z","timestamp":1792791949752,"version":"4.5.0"},"reference-count":149,"publisher":"American Society of Hematology","issue":"16","license":[{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders characterized by activated Janus kinase (JAK)\u2013signal transducer and activator of transcription signaling. As a result, JAK inhibitors have been the standard therapy for treatment of patients with myelofibrosis (MF). Although currently approved JAK inhibitors successfully ameliorate MPN-related symptoms, they are not known to substantially alter the MF disease course. Similarly, in essential thrombocythemia and polycythemia vera, treatments are primarily aimed at reducing the risk of cardiovascular and thromboembolic complications, with a watchful waiting approach often used in patients who are considered to be at a lower risk for thrombosis. However, better understanding of MPN biology has led to the development of rationally designed therapies, with the goal of not only addressing disease complications but also potentially modifying disease course. We review the most recent data elucidating mechanisms of disease pathogenesis and highlight emerging therapies that target MPN on several biologic levels, including JAK2-mutant MPN stem cells, JAK and non-JAK signaling pathways, mutant calreticulin, and the inflammatory bone marrow microenvironment.<\/jats:p>","DOI":"10.1182\/blood.2022017416","type":"journal-article","created":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T20:58:50Z","timestamp":1671483530000},"page":"1922-1933","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":65,"title":["Biology and therapeutic targeting of molecular mechanisms in MPNs"],"prefix":"10.1182","volume":"141","author":[{"given":"Joan","family":"How","sequence":"first","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA"},{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2118-6302","authenticated-orcid":false,"given":"Jacqueline S.","family":"Garcia","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9727-8495","authenticated-orcid":false,"given":"Ann","family":"Mullally","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA"},{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"3Cancer Program, Broad Institute, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"15","key":"2023110216015007000_bib1","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"2023110216015007000_bib2","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","article-title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","volume":"123","author":"Rampal","year":"2014","journal-title":"Blood"},{"issue":"10","key":"2023110216015007000_bib3","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia","volume":"123","author":"Rotunno","year":"2014","journal-title":"Blood"},{"issue":"7","key":"2023110216015007000_bib4","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"2023110216015007000_bib5","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-017-0527-7","article-title":"Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J\u00a0Hematol Oncol"},{"issue":"13","key":"2023110216015007000_bib6","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1002\/cncr.34205","article-title":"Defining disease modification in myelofibrosis in the era of targeted therapy","volume":"128","author":"Pemmaraju","year":"2022","journal-title":"Cancer"},{"issue":"11","key":"2023110216015007000_bib7","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/ajh.26349","article-title":"2021 update on allogeneic hematopoietic stem cell transplant for myelofibrosis: a review of current data and applications on risk stratification and management","volume":"96","author":"Ali","year":"2021","journal-title":"Am J Hematol"},{"issue":"16","key":"2023110216015007000_bib8","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1182\/blood.2020008109","article-title":"The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms","volume":"137","author":"Hasselbalch","year":"2021","journal-title":"Blood"},{"issue":"9464","key":"2023110216015007000_bib9","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"issue":"7037","key":"2023110216015007000_bib10","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A\u00a0unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"17","key":"2023110216015007000_bib11","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A\u00a0gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2023110216015007000_bib12","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"16","key":"2023110216015007000_bib13","doi-asserted-by":"crossref","first-page":"6224","DOI":"10.1073\/pnas.0601462103","article-title":"The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation","volume":"103","author":"Jamieson","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"2023110216015007000_bib14","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2006-04-017392","article-title":"Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera","volume":"108","author":"Ishii","year":"2006","journal-title":"Blood"},{"issue":"1","key":"2023110216015007000_bib15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2006-03-007146","article-title":"Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis","volume":"109","author":"Delhommeau","year":"2007","journal-title":"Blood"},{"issue":"25","key":"2023110216015007000_bib16","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2023110216015007000_bib17","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood-2007-05-089003","article-title":"Evidence for MPL W515L\/K mutations in hematopoietic stem cells in primitive myelofibrosis","volume":"110","author":"Chalign\u00e9","year":"2007","journal-title":"Blood"},{"issue":"14","key":"2023110216015007000_bib18","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"issue":"5","key":"2023110216015007000_bib19","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.hoc.2012.07.007","article-title":"Myeloproliferative neoplasm animal models","volume":"26","author":"Mullally","year":"2012","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"2023110216015007000_bib20","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1038\/s41467-020-18691-3","article-title":"Calreticulin del52 and ins5 knock-in mice recapitulate different myeloproliferative phenotypes observed in patients with MPN","volume":"11","author":"Benlabiod","year":"2020","journal-title":"Nat Commun"},{"issue":"6","key":"2023110216015007000_bib21","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood-2017-09-806356","article-title":"Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage","volume":"131","author":"Li","year":"2018","journal-title":"Blood"},{"issue":"26","key":"2023110216015007000_bib22","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2023110216015007000_bib23","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.stem.2021.02.001","article-title":"Reconstructing the lineage histories and differentiation trajectories of individual cancer cells in myeloproliferative neoplasms","volume":"28","author":"Van Egeren","year":"2021","journal-title":"Cell Stem Cell"},{"issue":"7895","key":"2023110216015007000_bib24","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41586-021-04312-6","article-title":"Life histories of myeloproliferative neoplasms inferred from phylogenies","volume":"602","author":"Williams","year":"2022","journal-title":"Nature"},{"issue":"6","key":"2023110216015007000_bib25","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/s41591-022-01793-4","article-title":"In utero origin of myelofibrosis presenting in adult monozygotic twins","volume":"28","author":"Sousos","year":"2022","journal-title":"Nat Med"},{"issue":"37","key":"2023110216015007000_bib26","doi-asserted-by":"crossref","first-page":"e2120374119","DOI":"10.1073\/pnas.2120374119","article-title":"Inferring the initiation and development of myeloproliferative neoplasms","volume":"119","author":"Hermange","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"2023110216015007000_bib27","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood"},{"issue":"10","key":"2023110216015007000_bib28","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"issue":"7831","key":"2023110216015007000_bib29","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41586-020-2786-7","article-title":"Inherited myeloproliferative neoplasm risk affects haematopoietic stem cells","volume":"586","author":"Bao","year":"2020","journal-title":"Nature"},{"issue":"6","key":"2023110216015007000_bib30","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.molcel.2019.01.009","article-title":"Unravelling intratumoral heterogeneity through high-sensitivity single-cell mutational analysis and parallel RNA sequencing","volume":"73","author":"Rodriguez-Meira","year":"2019","journal-title":"Mol Cell"},{"issue":"7","key":"2023110216015007000_bib31","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"2023110216015007000_bib32","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2011-04-348144","article-title":"TNF\u03b1 facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms","volume":"118","author":"Fleischman","year":"2011","journal-title":"Blood"},{"issue":"18","key":"2023110216015007000_bib33","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood.2019004095","article-title":"Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN","volume":"136","author":"Gleitz","year":"2020","journal-title":"Blood"},{"issue":"6","key":"2023110216015007000_bib34","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/ncb3530","article-title":"Leptin-receptor-expressing bone marrow stromal cells are myofibroblasts in primary myelofibrosis","volume":"19","author":"Decker","year":"2017","journal-title":"Nat Cell Biol"},{"issue":"4","key":"2023110216015007000_bib35","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.stem.2020.11.004","article-title":"Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis","volume":"28","author":"Leimk\u00fchler","year":"2021","journal-title":"Cell Stem Cell"},{"issue":"8617","key":"2023110216015007000_bib36","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S0140-6736(88)92625-6","article-title":"Treatment of essential thrombocythaemia by alpha 2a interferon","volume":"2","author":"Bellucci","year":"1988","journal-title":"Lancet"},{"issue":"8607","key":"2023110216015007000_bib37","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(88)92881-4","article-title":"Recombinant interferon-alpha for treatment of polycythaemia vera","volume":"2","author":"Silver","year":"1988","journal-title":"Lancet"},{"issue":"8","key":"2023110216015007000_bib38","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"issue":"32","key":"2023110216015007000_bib39","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alfa-2a yields high rates of hematologic and\u00a0molecular response in patients with advanced essential thrombocythemia and polycythemia vera","volume":"27","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2023110216015007000_bib40","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1182\/blood-2013-04-498956","article-title":"JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFN\u03b1","volume":"122","author":"Hasan","year":"2013","journal-title":"Blood"},{"issue":"18","key":"2023110216015007000_bib41","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1182\/blood-2012-05-432989","article-title":"Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-\u03b1 in a murine model of polycythemia vera","volume":"121","author":"Mullally","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2023110216015007000_bib42","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.exphem.2015.05.013","article-title":"Comparative long-term effects of interferon \u03b1 and hydroxyurea on human hematopoietic progenitor cells","volume":"43","author":"King","year":"2015","journal-title":"Exp Hematol"},{"issue":"22","key":"2023110216015007000_bib43","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2021010986","article-title":"Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFN\u03b1 in myeloproliferative neoplasms","volume":"138","author":"Mosca","year":"2021","journal-title":"Blood"},{"issue":"16","key":"2023110216015007000_bib44","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1182\/blood.2020005563","article-title":"JAK2-V617F and interferon-\u03b1 induce megakaryocyte-biased stem cells characterized by decreased long-term functionality","volume":"137","author":"Rao","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2023110216015007000_bib45","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s41375-019-0638-y","article-title":"Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations","volume":"34","author":"Austin","year":"2020","journal-title":"Leukemia"},{"issue":"7","key":"2023110216015007000_bib46","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1182\/bloodadvances.2021004856","article-title":"Genomic profiling of a randomized trial of interferon-\u03b1 vs hydroxyurea in MPN reveals mutation-specific responses","volume":"6","author":"Knudsen","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"2023110216015007000_bib47","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/s41375-018-0295-6","article-title":"JAK2V617F but not CALR mutations confer increased molecular responses to interferon-\u03b1 via JAK1\/STAT1 activation","volume":"33","author":"Czech","year":"2019","journal-title":"Leukemia"},{"issue":"19","key":"2023110216015007000_bib48","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood.2021012743","article-title":"A\u00a0randomized phase 3 trial of interferon-\u03b1 vs hydroxyurea in polycythemia vera and essential thrombocythemia","volume":"139","author":"Mascarenhas","year":"2022","journal-title":"Blood"},{"issue":"3","key":"2023110216015007000_bib49","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"Gisslinger","year":"2020","journal-title":"Lancet Haematol"},{"issue":"5","key":"2023110216015007000_bib50","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41375-022-01528-x","article-title":"Long-term outcomes of polycythemia vera patients treated with ropeginterferon alfa-2b","volume":"36","author":"Kiladjian","year":"2022","journal-title":"Leukemia"},{"issue":"12","key":"2023110216015007000_bib51","first-page":"2565","article-title":"Transcriptional induction of the PML growth suppressor gene by interferons is mediated through an ISRE and a GAS element","volume":"11","author":"Stadler","year":"1995","journal-title":"Oncogene"},{"issue":"2","key":"2023110216015007000_bib52","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201268","article-title":"JAK2V617F myeloproliferative neoplasm eradication by a novel interferon\/arsenic therapy involves PML","volume":"218","author":"Dagher","year":"2021","journal-title":"J Exp Med"},{"issue":"1","key":"2023110216015007000_bib53","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1038\/s41467-022-29381-7","article-title":"Discovery of a signaling feedback circuit that defines interferon responses in myeloproliferative neoplasms","volume":"13","author":"Saleiro","year":"2022","journal-title":"Nat Commun"},{"issue":"9","key":"2023110216015007000_bib54","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.3324\/haematol.2019.235648","article-title":"Ruxolitinib and interferon-\u03b12 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study","volume":"105","author":"S\u00f8rensen","year":"2020","journal-title":"Haematologica"},{"issue":"8","key":"2023110216015007000_bib55","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/nsmb.2348","article-title":"Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F","volume":"19","author":"Bandaranayake","year":"2012","journal-title":"Nat Struct Mol Biol"},{"issue":"6589","key":"2023110216015007000_bib56","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1126\/science.abn8933","article-title":"Structure of a Janus kinase cytokine receptor complex reveals the basis for dimeric activation","volume":"376","author":"Glassman","year":"2022","journal-title":"Science"},{"issue":"9","key":"2023110216015007000_bib57","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A\u00a0double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2023110216015007000_bib58","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2023110216015007000_bib59","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2023110216015007000_bib60","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/leu.2013.205","article-title":"Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348)","volume":"28","author":"Zhou","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"2023110216015007000_bib61","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol"},{"key":"2023110216015007000_bib62","first-page":"11","article-title":"Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor","volume":"8","author":"Singer","year":"2016","journal-title":"J\u00a0Exp Pharmacol"},{"issue":"22","key":"2023110216015007000_bib63","doi-asserted-by":"crossref","first-page":"5825","DOI":"10.1182\/bloodadvances.2020003314","article-title":"Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis","volume":"4","author":"Gerds","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"2023110216015007000_bib64","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","article-title":"Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial","volume":"4","author":"Mesa","year":"2017","journal-title":"Lancet Haematol"},{"issue":"12","key":"2023110216015007000_bib65","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJMra1804281","article-title":"Anemia of inflammation","volume":"381","author":"Ganz","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"2023110216015007000_bib66","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1182\/bloodadvances.2020002662","article-title":"ACVR1\/JAK1\/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial","volume":"4","author":"Oh","year":"2020","journal-title":"Blood Adv"},{"issue":"34","key":"2023110216015007000_bib67","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","article-title":"SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor\u2013na\u00efve patients with myelofibrosis","volume":"35","author":"Mesa","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"2023110216015007000_bib68","unstructured":"National Comprehensive Cancer Network, Myeloproliferative Neoplasms Version 2, 2022. Accessed 11 September 2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mpn.pdf."},{"issue":"suppl 16","key":"2023110216015007000_bib69","doi-asserted-by":"crossref","first-page":"7002","DOI":"10.1200\/JCO.2022.40.16_suppl.7002","article-title":"MOMENTUM: phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor","volume":"40","author":"Mesa","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2023110216015007000_bib70","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/leu.2013.71","article-title":"Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"27","author":"Pardanani","year":"2013","journal-title":"Leukemia"},{"issue":"6","key":"2023110216015007000_bib71","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/bjh.13644","article-title":"Ruxolitinib is an effective treatment for CALR-positive patients with myelofibrosis","volume":"173","author":"Guglielmelli","year":"2015","journal-title":"Br J Haematol"},{"issue":"7414","key":"2023110216015007000_bib72","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nature11303","article-title":"Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy","volume":"489","author":"Koppikar","year":"2012","journal-title":"Nature"},{"key":"2023110216015007000_bib73","doi-asserted-by":"crossref","unstructured":"Dunbar\n              A\n            , BowmanRL, ParkY, . Jak2V617F reversible activation shows an essential requirement for Jak2V617F in myeloproliferative neoplasms. bioRxiv. Preprint posted online 18 May 2022. https:\/\/doi.org\/10.1101\/2022.05.18.492332.","DOI":"10.1182\/blood-2022-164827"},{"issue":"10","key":"2023110216015007000_bib74","doi-asserted-by":"crossref","first-page":"e0221635","DOI":"10.1371\/journal.pone.0221635","article-title":"A\u00a0conditional inducible JAK2V617F transgenic mouse model reveals myeloproliferative disease that is reversible upon switching off transgene expression","volume":"14","author":"Chapeau","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"2023110216015007000_bib75","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ccell.2015.06.006","article-title":"CHZ868, a type II JAK2 inhibitor, reverses type I JAK inhibitor persistence and demonstrates efficacy in myeloproliferative neoplasms","volume":"28","author":"Meyer","year":"2015","journal-title":"Cancer Cell"},{"issue":"suppl 1","key":"2023110216015007000_bib76","article-title":"The second generation type II JAK2 inhibitor, AJ1- 10502, demonstrates enhanced selectivity, improved therapeutic efficacy and reduced mutant cell fraction compared to type I JAK2 inhibitors in models of myeloproliferative neoplasms (MPNs) [abstract]","volume":"140","author":"Rai","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2023110216015007000_bib77","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41375-021-01336-9","article-title":"Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2","volume":"36","author":"Yang","year":"2022","journal-title":"Leukemia"},{"issue":"23","key":"2023110216015007000_bib78","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1182\/blood.2020006846","article-title":"Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia","volume":"138","author":"Chang","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2023110216015007000_bib79","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol"},{"key":"2023110216015007000_bib80","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1182\/blood-2021-148995","article-title":"Treatment of myelofibrosis patients with the TGF-\u03b2 1\/3 inhibitor AVID200 (MPN-RC 118) induces a profound effect on platelet production","volume":"138","author":"Mascarenhas","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2023110216015007000_bib81","article-title":"A phase 2 study of the LSD1 inhibitor Img-7289 (bomedemstat) for the treatment of advanced myelofibrosis [abstract]","volume":"138","author":"Gill","year":"2021","journal-title":"Blood"},{"issue":"26","key":"2023110216015007000_bib82","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1200\/JCO.20.02864","article-title":"Randomized, single-blind, multicenter phase II study of two doses of imetelstat in relapsed or refractory myelofibrosis","volume":"39","author":"Mascarenhas","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"2023110216015007000_bib83","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-147543","article-title":"Potential disease-modifying activity of navtemadlin (KRT-232), a first-in-class MDM2 inhibitor, correlates with clinical benefits in relapsed\/refractory myelofibrosis (MF) [abstract]","volume":"138","author":"Vachani","year":"2021","journal-title":"Blood"},{"issue":"15","key":"2023110216015007000_bib84","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1200\/JCO.21.02188","article-title":"Addition of navitoclax to ongoing ruxolitinib therapy for patients with myelofibrosis with progression or suboptimal response: phase II safety and efficacy","volume":"40","author":"Harrison","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 13","key":"2023110216015007000_bib85","first-page":"CT162","article-title":"Abstract CT162: Addition of parsaclisib (INCB050465), a PI3K\u03b4 inhibitor, in patients with suboptimal response to ruxolitinib: A phase 2 study in patients with myelofibrosis","volume":"81","author":"Yacoub","year":"2021","journal-title":"Clin Trials"},{"issue":"suppl 1","key":"2023110216015007000_bib86","article-title":"Pelabresib (CPI-0610) monotherapy in patients with myelofibrosis-update of clinical and translational data from the ongoing manifest trial [abstract]","volume":"138","author":"Kremyanskaya","year":"2021","journal-title":"Blood"},{"key":"2023110216015007000_bib87","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/01.HS9.0000843684.97625.7e","article-title":"S198: BET inhibitor pelabresib (CPI-0610) combined with ruxolitinib in patients with myelofibrosis\u2014JAK inhibitor-na\u00efve or with suboptimal response to ruxolitinib\u2014preliminary data from the manifest study","volume":"6","author":"Mascarenhas","year":"2022","journal-title":"HemaSphere"},{"issue":"suppl 1","key":"2023110216015007000_bib88","article-title":"A phase 2 study to evaluate the efficacy and safety of selinexor in patients with myelofibrosis refractory or intolerant to JAK inhibitors [abstract]","volume":"138","author":"Tantravahi","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2023110216015007000_bib89","article-title":"A phase 1\/2 study of single agent tagraxofusp, a firstin- class CD123-targeted therapy, in patients with myelofibrosis that is relapsed\/refractory following JAK inhibitor therapy [abstract]","volume":"138","author":"Yacoub","year":"2021","journal-title":"Blood"},{"issue":"suppl 16","key":"2023110216015007000_bib90","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1200\/JCO.2022.40.16_suppl.7003","article-title":"Rusfertide (PTG-300) treatment in phlebotomy-dependent polycythemia vera patients","volume":"40","author":"Hoffman","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"2023110216015007000_bib91","article-title":"Rusfertide (PTG-300) induction therapy rapidly achieves hematocrit control in polycythemia vera patients without the need for therapeutic phlebotomy [abstract]","volume":"138","author":"Ginzburg","year":"2021","journal-title":"Blood"},{"key":"2023110216015007000_bib92","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/01.HS9.0000847000.38667.91","article-title":"P1033: a phase 2 study of the LSD1 inhibitor IMG-7289 (bomedemstat) for the treatment of essential thrombocythemia (ET)","volume":"6","author":"Palandri","year":"2022","journal-title":"HemaSphere"},{"issue":"1","key":"2023110216015007000_bib93","doi-asserted-by":"crossref","first-page":"e54826","DOI":"10.1371\/journal.pone.0054826","article-title":"mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms","volume":"8","author":"Bogani","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"2023110216015007000_bib94","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1172\/JCI98785","article-title":"Targeting compensatory MEK\/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms","volume":"129","author":"Stivala","year":"2019","journal-title":"J\u00a0Clin Invest"},{"issue":"10","key":"2023110216015007000_bib95","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1038\/s41375-021-01391-2","article-title":"Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy","volume":"35","author":"Brkic","year":"2021","journal-title":"Leukemia"},{"issue":"279","key":"2023110216015007000_bib96","doi-asserted-by":"crossref","first-page":"279ra240","DOI":"10.1126\/scitranslmed.aaa4642","article-title":"Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy","volume":"7","author":"Leverson","year":"2015","journal-title":"Sci Transl Med"},{"issue":"357","key":"2023110216015007000_bib97","doi-asserted-by":"crossref","first-page":"ra122","DOI":"10.1126\/scisignal.2005301","article-title":"RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis","volume":"7","author":"Winter","year":"2014","journal-title":"Sci Signal"},{"issue":"4","key":"2023110216015007000_bib98","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.celrep.2013.10.038","article-title":"Combined targeting of JAK2 and Bcl-2\/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors","volume":"5","author":"Waibel","year":"2013","journal-title":"Cell Rep"},{"issue":"3","key":"2023110216015007000_bib99","doi-asserted-by":"crossref","first-page":"e0114363","DOI":"10.1371\/journal.pone.0114363","article-title":"JAK2V617F drives Mcl-1 expression and sensitizes hematologic cell lines to dual inhibition of JAK2 and Bcl-xL","volume":"10","author":"Guo","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"2023110216015007000_bib100","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.1016\/S2352-3026(22)00116-8","article-title":"Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study","volume":"9","author":"Pemmaraju","year":"2022","journal-title":"Lancet Haematol"},{"issue":"17","key":"2023110216015007000_bib101","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","article-title":"MIPSS70+ version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for primary myelofibrosis","volume":"36","author":"Tefferi","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2023110216015007000_bib102","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood-2015-03-633404","article-title":"Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib","volume":"126","author":"Patel","year":"2015","journal-title":"Blood"},{"issue":"20","key":"2023110216015007000_bib103","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/bloodadvances.2017009530","article-title":"Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1\/2 inhibitor therapy","volume":"1","author":"Spiegel","year":"2017","journal-title":"Blood Adv"},{"issue":"1","key":"2023110216015007000_bib104","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ccell.2017.11.009","article-title":"Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms","volume":"33","author":"Kleppe","year":"2018","journal-title":"Cancer Cell"},{"issue":"8","key":"2023110216015007000_bib105","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1084\/jem.20151121","article-title":"The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition","volume":"213","author":"Sashida","year":"2016","journal-title":"J\u00a0Exp Med"},{"issue":"3","key":"2023110216015007000_bib106","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood-2017-06-789669","article-title":"Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies","volume":"131","author":"Yang","year":"2018","journal-title":"Blood"},{"issue":"7384","key":"2023110216015007000_bib107","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nature10805","article-title":"Enhancer decommissioning by LSD1 during embryonic stem cell differentiation","volume":"482","author":"Whyte","year":"2012","journal-title":"Nature"},{"issue":"6199","key":"2023110216015007000_bib108","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1126\/science.1256271","article-title":"Immunogenetics. chromatin state dynamics during blood formation","volume":"345","author":"Lara-Astiaso","year":"2014","journal-title":"Science"},{"issue":"9","key":"2023110216015007000_bib109","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1038\/leu.2012.157","article-title":"Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation","volume":"26","author":"Spr\u00fcssel","year":"2012","journal-title":"Leukemia"},{"issue":"1","key":"2023110216015007000_bib110","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1182\/blood-2014-04-569525","article-title":"Lysine-specific demethylase 1 (LSD1) in hematopoietic and lymphoid neoplasms","volume":"124","author":"Niebel","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2023110216015007000_bib111","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1097\/HS9.0000000000000054","article-title":"LSD1 inhibition prolongs survival in mouse models of MPN by selectively targeting the disease clone","volume":"2","author":"Jutzi","year":"2018","journal-title":"Hemasphere"},{"issue":"suppl 1","key":"2023110216015007000_bib112","article-title":"A phase 2 study of the LSD1 inhibitor Img- 7289 (bomedemstat) for the treatment of essential thrombocythemia (ET) [abstract]","volume":"138","author":"Palandri","year":"2021","journal-title":"Blood"},{"issue":"15","key":"2023110216015007000_bib113","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1182\/blood-2017-09-807024","article-title":"LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C\/EBP\u03b1-dependent enhancers in AML","volume":"131","author":"Cusan","year":"2018","journal-title":"Blood"},{"issue":"13","key":"2023110216015007000_bib114","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1016\/j.celrep.2018.03.012","article-title":"Enhancer activation by pharmacologic displacement of LSD1 from GFI1 induces differentiation in acute myeloid leukemia","volume":"22","author":"Maiques-Diaz","year":"2018","journal-title":"Cell Rep"},{"issue":"5","key":"2023110216015007000_bib115","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41589-019-0263-0","article-title":"CRISPR-suppressor scanning reveals a nonenzymatic role of LSD1 in AML","volume":"15","author":"Vinyard","year":"2019","journal-title":"Nat Chem Biol"},{"issue":"5659","key":"2023110216015007000_bib116","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1126\/science.1092472","article-title":"In\u00a0vivo activation of the p53 pathway by small-molecule antagonists of MDM2","volume":"303","author":"Vassilev","year":"2004","journal-title":"Science"},{"issue":"21","key":"2023110216015007000_bib117","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.4582.4582","article-title":"Imetelstat (GRN163L), a telomerase inhibitor selectively affects malignant megakaryopoiesis in myeloproliferative neoplasms (MPN) [abstract]","volume":"124","author":"Iancu-Rubin","year":"2014","journal-title":"Blood"},{"issue":"15","key":"2023110216015007000_bib118","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1182\/blood-2018-08-872648","article-title":"CDK6 coordinates JAK2 (V617F) mutant MPN via NF-\u03baB and apoptotic networks","volume":"133","author":"Uras","year":"2019","journal-title":"Blood"},{"issue":"16","key":"2023110216015007000_bib119","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.1158\/0008-5472.CAN-21-0590","article-title":"CDK6 is a therapeutic target in myelofibrosis","volume":"81","author":"Dutta","year":"2021","journal-title":"Cancer Res"},{"issue":"12","key":"2023110216015007000_bib120","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1158\/1078-0432.CCR-20-4898","article-title":"Therapeutic efficacy of combined JAK1\/2,\u00a0Pan-PIM, and CDK4\/6 inhibition in myeloproliferative neoplasms","volume":"27","author":"Rampal","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2023110216015007000_bib121","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/s41375-018-0207-9","article-title":"Dysregulated iron metabolism in polycythemia vera: etiology and consequences","volume":"32","author":"Ginzburg","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"2023110216015007000_bib122","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2015-10-676742","article-title":"Minihepcidin peptides as disease modifiers in mice affected by \u03b2-thalassemia and polycythemia vera","volume":"128","author":"Casu","year":"2016","journal-title":"Blood"},{"issue":"25","key":"2023110216015007000_bib123","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"2023110216015007000_bib124","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood.2019000622","article-title":"Mutant calreticulin in myeloproliferative neoplasms","volume":"134","author":"How","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2023110216015007000_bib125","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1158\/2159-8290.CD-15-1434","article-title":"Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation","volume":"6","author":"Elf","year":"2016","journal-title":"Cancer Discov"},{"issue":"10","key":"2023110216015007000_bib126","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1182\/blood-2015-09-671172","article-title":"Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms","volume":"127","author":"Araki","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2023110216015007000_bib127","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood-2015-11-681932","article-title":"Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants","volume":"127","author":"Chachoua","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2023110216015007000_bib128","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41375-018-0181-2","article-title":"Homomultimerization of mutant calreticulin is a prerequisite for MPL binding and activation","volume":"33","author":"Araki","year":"2019","journal-title":"Leukemia"},{"issue":"7","key":"2023110216015007000_bib129","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1182\/bloodadvances.2020002402","article-title":"Zinc-dependent multimerization of mutant calreticulin is required for MPL binding and MPN pathogenesis","volume":"5","author":"Rivera","year":"2021","journal-title":"Blood Adv"},{"issue":"7","key":"2023110216015007000_bib130","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1182\/blood-2017-08-800896","article-title":"Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN","volume":"131","author":"Elf","year":"2018","journal-title":"Blood"},{"issue":"25","key":"2023110216015007000_bib131","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1182\/blood-2018-09-874578","article-title":"Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants","volume":"133","author":"Pecquet","year":"2019","journal-title":"Blood"},{"issue":"11","key":"2023110216015007000_bib132","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1182\/blood.2022015629","article-title":"Whole-genome CRISPR screening identifies N-glycosylation as a genetic and therapeutic vulnerability in CALR-mutant MPN","volume":"140","author":"Jutzi","year":"2022","journal-title":"Blood"},{"issue":"22","key":"2023110216015007000_bib133","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.122703","article-title":"Targeting the CALR interactome in myeloproliferative neoplasms","volume":"3","author":"Pronier","year":"2018","journal-title":"JCI Insight"},{"issue":"4","key":"2023110216015007000_bib134","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1158\/2643-3230.BCD-21-0144","article-title":"Type I but not type II calreticulin mutations activate the IRE1\u03b1\/XBP1 pathway of the unfolded protein response to drive myeloproliferative neoplasms","volume":"3","author":"Ibarra","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"2","key":"2023110216015007000_bib135","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41375-022-01781-0","article-title":"CALR-mutated cells are vulnerable to combined inhibition of the proteasome and the endoplasmic reticulum stress response","volume":"37","author":"Jutzi","year":"2023","journal-title":"Leukemia"},{"issue":"4","key":"2023110216015007000_bib136","doi-asserted-by":"crossref","first-page":"e52904","DOI":"10.15252\/embr.202152904","article-title":"Targeting human CALR-mutated MPN progenitors with a neoepitope-directed monoclonal antibody","volume":"23","author":"Tvorogov","year":"2022","journal-title":"EMBO Rep"},{"issue":"6","key":"2023110216015007000_bib137","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/ajh.26171","article-title":"Hematopoietic expression of a chimeric murine-human CALR oncoprotein allows the assessment of anti-CALR antibody immunotherapies in\u00a0vivo","volume":"96","author":"Achyutuni","year":"2021","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"2023110216015007000_bib138","article-title":"Therapeutic potential of an antibody targeting the cleaved form of mutant calreticulin in myeloproliferative neoplasms [abstract]","volume":"36","author":"Kihara","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2023110216015007000_bib139","article-title":"Discovery of INCA033989, a monoclonal antibody that selectively antagonizes mutant calreticulin oncogenic function in myeloproliferative neoplasms (MPNs) [abstract]","volume":"140","author":"Reis","year":"2022","journal-title":"Blood"},{"issue":"649","key":"2023110216015007000_bib140","doi-asserted-by":"crossref","first-page":"eaba4380","DOI":"10.1126\/scitranslmed.aba4380","article-title":"Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine","volume":"14","author":"Gigoux","year":"2022","journal-title":"Sci Transl Med"},{"issue":"2","key":"2023110216015007000_bib141","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41408-018-0166-4","article-title":"High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals","volume":"9","author":"Holmstr\u00f6m","year":"2019","journal-title":"Blood Cancer J"},{"issue":"9","key":"2023110216015007000_bib142","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1158\/2159-8290.CD-18-1356","article-title":"Immune checkpoint blockade enhances shared neoantigen-induced T-cell immunity directed against mutated calreticulin in myeloproliferative neoplasms","volume":"9","author":"Cimen Bozkus","year":"2019","journal-title":"Cancer Discov"},{"issue":"23","key":"2023110216015007000_bib143","doi-asserted-by":"crossref","first-page":"5086","DOI":"10.1182\/bloodadvances.2021005491","article-title":"PD-1 inhibition in advanced myeloproliferative neoplasms","volume":"5","author":"Hobbs","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"2023110216015007000_bib144","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s40425-018-0386-y","article-title":"Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies","volume":"6","author":"Tubb","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"key":"2023110216015007000_bib145","doi-asserted-by":"crossref","first-page":"637420","DOI":"10.3389\/fonc.2021.637420","article-title":"Therapeutic cancer vaccination with a peptide derived from the\u00a0calreticulin exon 9 mutations induces strong cellular immune responses in patients\u00a0with CALR-mutant chronic myeloproliferative neoplasms","volume":"11","author":"Handlos Grauslund","year":"2021","journal-title":"Front Oncol"},{"key":"2023110216015007000_bib146","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2016.377","article-title":"Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia","author":"Fisher","year":"2017;31(9):1962-1974","journal-title":"Leukemia"},{"key":"2023110216015007000_bib147","doi-asserted-by":"crossref","DOI":"10.1038\/s41563-022-01293-3","article-title":"Mechanical checkpoint regulates monocyte differentiation in fibrotic niches","author":"Vining","year":"2022;21(8):939-950","journal-title":"Nat Mater"},{"issue":"6","key":"2023110216015007000_bib148","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.stem.2017.03.008","article-title":"Gli1(+) mesenchymal stromal cells are a key driver of bone marrow fibrosis and an important cellular therapeutic target","volume":"20","author":"Schneider","year":"2017","journal-title":"Cell Stem Cell"},{"issue":"11","key":"2023110216015007000_bib149","doi-asserted-by":"crossref","first-page":"e154092","DOI":"10.1172\/JCI154092","article-title":"TGF-\u03b2 signaling in myeloproliferative neoplasms contributes to myelofibrosis without disrupting the hematopoietic niche","volume":"132","author":"Yao","year":"2022","journal-title":"J Clin Invest"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/16\/1922\/2087811\/blood_bld-2022-017416-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/16\/1922\/2087811\/blood_bld-2022-017416-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T16:04:13Z","timestamp":1698941053000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/141\/16\/1922\/493768\/Biology-and-therapeutic-targeting-of-molecular"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":149,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2023,4,20]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022017416","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,20]]}}}